Aardvark Therapeutics Reports Increased Q1 Net Loss Amidst Clinical Trial Pauses; Cash Runway into Mid-2027

summarizeSummary

Aardvark Therapeutics reported a significantly increased net loss for Q1 2026, driven by higher R&D expenses, and confirmed the voluntary pause of its main clinical trials due to safety observations. The company maintains a cash runway into mid-2027 and has a $150 million ATM facility in place, though no shares have been sold under it as of March 31, 2026.

check_boxKey Events

• Increased Net Loss

  The company reported a net loss of $21.6 million for Q1 2026, a substantial increase from $9.3 million in Q1 2025.

• Higher R&D Expenses

  Research and development expenses rose to $16.6 million in Q1 2026, up from $7.8 million in Q1 2025, reflecting increased clinical activity prior to the trial pauses.

• Clinical Trial Pauses Confirmed

  The filing reiterates the voluntary pause of Phase 3 HERO (ARD-101) and Phase 2 POWER and STRENGTH (ARD-201) clinical trials in February 2026 due to reversible cardiac observations in a healthy volunteer study. Further guidance is expected in Q2 2026.

• Liquidity and Cash Runway

  Aardvark Therapeutics held $91.2 million in cash, cash equivalents, and short-term investments as of March 31, 2026, projecting a cash runway into mid-2027.

auto_awesomeAnalysis

Aardvark Therapeutics' Q1 2026 results highlight a significant increase in net loss and R&D expenses, primarily driven by clinical trial activities before the voluntary pause of its key programs. The reiteration of the trial pauses for ARD-101 and ARD-201 due to cardiac observations remains a critical concern for this clinical-stage biopharmaceutical company. While the company has established a $150 million At-The-Market (ATM) facility, no shares have been sold yet, indicating potential future dilution. The reported cash runway into mid-2027 provides some near-term stability, but the company will require substantial additional funding to advance its pipeline, especially given the uncertainties surrounding its paused clinical programs.